Please describe your practice as a clinician,how many patients with wet AMD do you treat on a yearly basis? Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.

Please comment on the trial results main findings:-RGX-314 continues to be well tolerated in 85 patients from Cohorts 1-5 with no drug-related serious adverse events-Meaningful reduction in treatment burden at six months across all dose levels, 85% reduction in treatment burden observed at third dose level-67% of patients in Cohort 4 were injection-free-No meaningful differences in outcomes at six months for patients who are NAb positive

Please comment on SAEs reported in the trial, with conjunctival hemorrhage, increased intraocular pressure, episcleritis, and conjunctival hyperemia and mild intraocular inflammation reported at similar incidence in the first and second dose levels, with an increase in incidence in mild to moderate inflammation seen at the third dose level (Cohort 4).

How significant is the reported highest reduction in treatment burden observed in the third dose level, with patients receiving a mean of 1.3 injections over six months following administration of RGX-314, which represents an 84.7% reduction in anti-VEGF treatment burden?